On July 12th, Hutchmed (China) gained over 7% in Hong Kong stocks, leading to a pre-market trading increase of 4% for HCM.US, with a price of $8.5. Northeast Securities' research reports indicate that the company has made rapid development in recent R&D, with multiple products launched simultaneously, demonstrating excellent clinical data and competitive landscape. The company is continuously promoting its products globally, and is expected to continue to catalyze the value of the company's fundamentals. In addition, the company has abundant pipeline reserves and a broad product market space, continuously achieving overseas release. Maintain a 'buy' rating on the company.
美股异动 | 券商唱好 和黄医药盘前涨4% H股今日大幅收涨超7%
U.S. Stocks surged: brokerage optimistic about hutchmed (china), pre-market trading boosted by 4%; Listed in Hong Kong saw a significant increase of over 7% today.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.